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THE ROLE OF RNASE L IN TYPE I DIABETES AND
DEVELOPMENT OF QUANTITATIVE LC-MS/MS METHODS
FOR THE PHARMACOLOGICAL STUDIES OF ANTI-CANCER
DRUG CANDIDATES

CHUN ZENG

ABSTRACT
PROJECT I:
The cause of type I diabetes continues to be a focus of investigation. In this study, we
found that 2-5A dependent RNase L (RNase L), an IFN-α-inducible enzyme that
functions in IFN action against viruses and cell proliferation, played an important role
in dsRNA-induced onset of type I diabetes. By using RNase L deficient RIP-B7.1
mice which are more vulnerable to environmental harmful factors such as viral
infection, we demonstrated that deficiency of RNase L in mice resulted in a
significant delay of diabetes onset induced by polyinosinic:polycytidylic acid (poly
I:C), a type of dsRNA, and streptozotocin (STZ). Immunohistostaining showed that
the population of infiltrated CD8+ T-cells was remarkably reduced in the islets of
RNase L deficient mice, implicating RNase L may contribute to type I diabetes onset
through regulating immune responses. Furthermore, RNase L was responsible for the
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expression of certain proinflammatory genes in the pancreas under the special
condition.

PROJECT II:
It has been found that 6-hydroximino-4-aza-A-homo-cholest-3-one (HyM3) is a
steroidal derivative with a significant anticancer effect.
To develop a method for analyzing its pharmacological kinetics, HyM3 and the
internal standard (3E)-Hydroximinocholest-6-one were extracted from mouse plasma
samples through a protein precipitation procedure by mixing with acetonitrile (1:4 v/v)
and then centrifuging at 12,400 g for 15 minutes. The supernatant (10 µl) was injected
onto the LC/MS system consisting of a Shimadzu Prominence HPLC and an AB
Sciex QTrap 5500 with positive electrospray ionization. A MRM mode was chosen
for sensitive and specific detection of the analyte and internal standard. The HPLC
separation employed a Phenomenex Kinetex C8 column (50x2.1 mm, 2.6µ) with a
gradient mobile phase of 0.2% formic acid in water and 0.2% formic acid in
acetonitrile at a rate of 0.2 ml/min. Full mass spectrometric scans of HyM3 and the
internal standard showed protonated molecular ions of 431 and 416 m/z, and
fragmentation of these two ions revealed predominant product ions of 370 m/z and
344 m/z respectively. HyM3 was retained on the HPLC column for 6.4 minutes, while
the internal standard was retained for 7.3 minutes. The method was calibrated for a
concentration range from 0.500 to 200 ng of Hym3 per mL of plasma.
vi
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CHAPTER I
INTRODUCTION
Project I: The role of RNASE L in type I diabetes and
renal function
1.1 Overview of Type I Diabetes mellitus (DM)
Diabetes mellitus is associated with a variety of complications including blindness,
kidney failure, heart disease, painful nerve damage, and circulatory problems so
severe they necessitate amputation

[1-4]

. The Centers for Disease Control and

Prevention (CDC) reported in 2011 that more than 25.8 million Americans—8.3% of
the population—have diabetes. This number is predicted to be doubled in the next two
decades

[5]

. There are two types of diabetes: insulin-dependent diabetes mellitus

(IDDM) or juvenile-onset diabetes and non-insulin-dependent diabetes mellitus
(NIDDM). Diabetes costs the nation about $245 billion in 2012 [6].

1

1.1.1 Epidemiology of DM
Diabetes mellitus is caused by inherited and/or acquired deficiency in insulin
production by the pancreas, or by the ineffectiveness of the insulin produced. Such
deficiency or ineffectiveness results in increased concentrations of blood glucose,
which in turn damages many of the body’s system, in particular the blood vessels and
nerves. Type 1 and type 2 diabetes are the main forms of diabetes.

As one of the most common non-communicable disease worldwide, diabetes is one of
the most challenging health problems in the 21st century. In most developed countries,
diabetes is the fourth or fifth leading cause of death. Substantial evidence shows that
it is also epidemic in many developing countries. The incidence of diabetes is
increasing greatly worldwide. And this trend is likely to keep going in the future
decades.

(Figure 1-1 and figure 1-2)

2

Figure 1-1.The tread of the diabetes from 2000 to 2012, data from the Diabetes report
card, 2014

3

Diagnosed and undiagnosed diabetes among people aged 20 years or older, United
States, 2012

Figure 1-2. Data from the National Diabetes Statistics Report, 2014

1.1.2 The etiology of TIDM
The etiology of diabetes (Figure 1-3) continues to be a focus of investigation. Both
genetic and environmental factors such as toxins, viruses, and diets are believed to
4

play an important role in its pathogenesis

[7]

. A reduction of insulin producing

pancreatic β-cells has been considered as one of the key factors in the development of
diabetes, particularly in type I diabetes

[8,9]

. In type I diabetes, autoimmunological

destruction of the pancreatic β-cells results in an absolute loss of insulin production.
Investigation of the molecular mechanisms underlying β-cell destruction has revealed
that microbial infections recruit immune effectors mediating β-cell apoptosis, which
in turn triggers autoimmune responses

[9]

. The NOD mouse is an ideal model of

spontaneous type I diabetes, a T cell-mediated autoimmune disease. Histological
studies have shown that infiltration of immune cells including macrophages and
lymphocytes around the islets starts at 3 to 4 weeks of age, causing insulitis [10,11]. The
role of CD4+ and CD8+ T-cells in the onset of type I diabetes has been well
established in recent years. Clinical and animal studies have shown that CD8+ T cells
take a central stage in the destruction of pancreatic β-cells and contribute to sustaining
islet inflammation, leading to the onset of type I diabetes [10-13].

The expression of proinflammatory genes has been implicated in the pathogenesis of
type I diabetes [14]. In NOD mice, an increased expression of IFN-γ, TNF-α and IL-1β
is associated with β-cell destructive insulitis [10, 11]. In recent years the role of IFN-α in
autoimmune diseases including type I diabetes has been well established

[ 15 ]

.

Increased levels of IFN-α in the sera of type 1 diabetes patients have been
documented

[ 16 ]

. Transgenic mice expressing IFN-α in the β-cells develop
5

hypoinsulinemic diabetes associated with a mixed inflammation centered on the islet,
which can be prevented with a neutralizing antibody to IFN-α [17]. It has been reported
that the onset of type I diabetes in both the BB rat and STZ-treated mice is IFN-α
dependent

[18]

. In addition, IFN-α also mediates induction of type I diabetes by poly

I:C in the mice expressing the B7.1 costimulatory molecule on β-cells in islets [19].
Most recently, a study has revealed that blockade of IFN-α signaling by anti-IFNAR1
in 2- to 3-week old NOD mice remarkably delays the onset and decreases the
incidence of diabetes, suggesting the involvement of IFN-stimulated genes in the
pathogenesis of type I diabetes [20] (Figure 1-4 and 1-5).

Figure 1-3. The etiology of diabetes. ( Ermann et al , Nat Immunol. 2001)

6

Figure 1-4. Mechanisms of viral-induced type I Diabetes. (D. Devendra and G.S.
Eisenbarth Clinical Immunology. 2004)

7

Figure 1-5.

The effect of viral dsRNA and interferon alpha on the pathogenesis of

type I diabetes.

(D. Devendra and G.S. Eisenbarth Clinical Immunology. 2004)

1.2 Introduction of IFN
1.2.1 Type I IFN
Human type I IFNs comprise a vast and growing group of IFN proteins such as IFN-α,
IFN-β, IFN-κ, IFN-δ, IFN-ε, IFN-τ, IFN-ω and IFN-ζ. Type I IFNs are encoded by a
gene cluster located on the short arm of chromosome 9 in humans and chromosome 4
in mice. A map of the type I IFN gene contains 26 IFN genes and pseudogenes [21].
IFN-α that is produced by peripheral leukocytes (B cells and T-cells) and IFN-β that
is secreted by fibroblasts, are both the most studied subfamilies of type I IFN and both
8

of them can be induced in mammalian cells in response to viral infection. All IFN-α
genes encode for the same size primary proteins with 166 amino acids in length,
except IFN-α2 that encodes for 165 amino acids

[22]

. No evidence was found for the

existence of an intron, in either the coding or the non-coding segments of the gene [21].
IFN-α subfamily is up to 70% homologous at the protein level and from 80%-100% at
the nucleotide level. IFN-β shows from 25%-30% homology with the IFN-α
subfamily members at amino acid levels and 45% at the nucleotide level

[23]

. Type I

IFNs bind to a specific cell surface receptor complex that consists of IFNAR1 and
IFNAR2.

1.2.2 Type II IFN
INF-γ is the only member in type II IFN. The mature IFN-γ ligand is an anti-parallel
homodimer, and it binds to the IFN-γ receptor complex, which is made up of two of
each IFNγR1 and IFNγR2 subunits. It is produced in activated T-cells and natural
killer cells [24]. Human IFN-γ is a 146 amino acids protein N-glycosylated at two sites
and encoded on four exons, in contrary to intronless type I IFN[25]. The IFN-γ gene is
located on chromosome 12 in humans and chromosome 10 in mice. IFN-γ is involved
in the regulation of the immune and inflammatory responses. It is released by Th 1
cells and recruits leukocytes to a site of infection, resulting in increased inflammation.
It also stimulates macrophages to kill bacteria that have been engulfed. IFN-γ has

9

some anti-viral and anti-tumor effects, but these are generally weak; it, however,
potentiates the effects of IFN-α and IFN-β.

1.2.3 The signal transduction of IFNs
IFNs bind to completely different cell surface receptors; however, the signal
transduction pathways activated by the IFN-α/β and IFN-γ receptors partially overlap.
IFNs exert their actions through cognate cell surface receptors that are largely species
specific

[26]

. The α, β, and ω IFNs appear to have a common receptor consisting of

two subunits, IFNAR-1 and IFNAR-2. Binding of IFN α/β initiates the signaling
cascade by causing dimerization of the receptor subunits, IFNAR1 and IFNAR2. This
initial step triggers a conformation change that is propagated through the cell
membrane and is responsible for the initiation of the phosphorylation cascade.
IFN-mediated the signaling and transcriptional activation of cellular gene expression
are best understood in the context of JAK-STAT pathway [27]. There are seven known
members of the signal transducer and activator of transcription (STAT) family of
proteins, Stat-1, Stat-2, Stat-3, Stat-4, Stat-5a, Stat-5b, and Stat-6, and four members
of the Janus family of tyrosine kinase (JAK) enzymes, Jak-1, Jak-2, Jak-3, and Tyk-2.
STATs are latent cytoplasmic transcription factors that become tyrosine
phosphorylated by the JAK in response to cytokine stimulation. Different members of
the JAK and STAT families have distinct functions in cytokine signaling. Of the
known JAKs and STATs, the Jak-1, Jak-2, and Tyk-2 kinases and the Stat-1 and
10

Stat-2 transcription factors play central roles in mediating IFN-dependent biological
responses, including induction of the antiviral state

[ 28 ]

. The first intracellular

component of the signaling pathway that receives the “transduction pulse” is the JAK
kinase, Tyk2, which is pre-associated with IFNAR1. Upon interferon stimulation,
Tyk2 is immediately phosphorylated by JAK1, another JAK kinase, which is bound to
IFNAR2. Activated Tyk2 then in turn phosphorylates JAK1. The activated JAK
kinases, Tyk2 and JAK1, are responsible for the subsequent phosphorylation of
IFNAR1 and IFNAR2 at specific tyrosine residues. STAT2 then binds to specific
phosphorylated residues on IFNAR1. Upon docking, STAT2 is phosphorylated at a
conserved tyrosine residue (Y701) by the JAK kinases thereby creating an additional
docking port for STAT1, which is also subsequently phosphorylated at Y690. The
phosphorylated STATs then dissociate from the receptor heterodimer and bind to p48
(IRF9), a member of the IFN regulatory factor (IRF) family, forming the major IFN
transcription factor, known as ISGF-3. ISGF-3 translocates to the nucleus and binds to
specific regulatory DNA sequences (ISRE-IFN stimulated response elements) and
initiates transcription of IFN-inducible genes.

1.3 IFN-induced genes associated with its antiviral function
IFNs display their biological function via inducing IFN-stimulated genes (ISGs). The
well-studied ISGs associated with its antiviral action of IFNs are dsRNA-dependent
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protein kinase R (PKR), the 2’-5’oligoadenylate synthetase (OAS), RNase L, the Mx
protein GTPases [27].

1.3.1 Mx proteins
Mx proteins are synthesized in IFN-treated vertebrate cells. The name of these
proteins comes from their ability to inhibit the replication of myxoviruses, such as
influenza. In human, Mx gene products are designated as MxA, and MxB, whereas in
rat and murine species Mx gene products are designated as Mx1, Mx2, and Mx3. The
location of Mx proteins in specific compartments is related to their biological function.
Mx1 proteins are nuclear proteins and as a consequence of their location, they inhibit
influenza virus in the nucleus. The mechanism of how Mx proteins inhibit the
replication of different viruses is unknown. Proteins MxA and Mx1 of the Mx family
of proteins are possibly the best characterized of the known IFN-inducible gene
products with antiviral activity. It has been established that Mx alone is sufficient to
block the replication of virus in the absence of any other IFN α/β-inducible proteins
[27]

. Mx proteins are GTPases that belong to the superfamily of dynamin-like GTPases

[29]

. The intrinsic GTPase activity of Mx proteins is required for their antiviral activity.

The highly conserved tripartite GTP binding motif is present within the N-terminal
region of the 70- to 80-kDa proteins. Mx proteins associate with themselves and,
importantly, with viral protein complexes. The central and C-terminal regions of Mx
play important roles in these protein-protein interactions
12

[30]

. Mx is inducible by

IFN-α and IFN-β but not by IFN-γ

[31]

. The Mx proteins

[32]

plays a pivotal roles in

inhibiting two members of the Orthomyxoviridae family: influenza virus and Thogoto
virus. The human genome contains two related Mx proteins, MxA and MxB, which
are induced by IFN-α/β. The human MxA protein has 662 amino acids whereas the
MxB protein has 715 amino acids. Both human MxA and MxB are mapped to
chromosome 21. The MxA protein normally accumulates in the cytoplasm of
IFN-treated cells and possesses antiviral activity. The antiviral activity of MxA,
which undergoes oligomerization, is dependent upon GTP binding and hydrolysis.
Cells that constitutively express the human MxA protein show a high degree of
antiviral activity, displaying resistance to several members of the Orthomyxoviridae
including influenza A and C viruses and Thogoto virus. Interestingly, a number of
additional RNA viruses including members of the Bunyaviridae (LaCrosse virus,
Hantavirus), Paramyxoviridae (measles virus, parainfluenza 3), Rhabdoviridae (VSV),
and Togaviridae (Semliki Forest virus) are inhibited by MxA expression either in
cultured cells or in transgenic mice [27].

1.3.2 PKR
The pkr gene encoding the IFN-inducible, RNA-dependent protein kinase, PKR, was
isolated as lambda phage and P1 phage clones from human genomic DNA. The
genomic nucleotide sequence revealed 17 exons encoding the 551–amino acid PKR
protein

[33]

. PKR was known in the earlier literature as DAI or dsI; P1 kinase;
13

P1/eIF-2α kinase; p65, p67, or TIK (for the mouse enzyme); and p68 or p69 (for the
human enzyme)

[27]

. In IFN-treated cells, PKR is found predominantly in the

cytoplasm and associated with ribosomes; however, small amounts of PKR have also
been localized to the nucleus. The expression of PKR is rapidly stimulated by IFNs
and reaches levels approximately 5-10 folds higher than that in resting cells. This
action of IFN is mediated through an ISRE (IFN-stimulated regulatory element) and
GAS (gamma IFN-activated site) in the promoter region of the PKR gene. PKR
contains two conserved dsRNA-binding motifs at the amino-terminus, RI (amino
acids 55-75) and RII (amino acids 145-166). Both regions possess a similar core
sequence, but RI alone appears to be necessary and sufficient to mediate dsRNA
binding. It is believed that a combination of both domains creates a single binding site
where the different domains bind to different regions of the dsRNA molecule [27]. No
RNA sequence specificity has been identified. PKR is activated by double stranded
RNA (viral RNA or secondary RNA structures), which results in a conformational
change that uncovers the carboxyl-terminal catalytic domain of PKR. Approximately
50 bp of duplexed RNA are required for its full activation, although shorter stretches
of secondary structure on pre-dominantly single stranded RNA can activate PKR.
This

activates

the

kinase

activity

of

PKR,

which

then

undergoes

autophosphorylation/activation in several serine and threonine residues. The activated
kinase phosphorylates in turn the translation initiation factor eIF2-α at Ser51,
resulting in inhibition of viral protein synthesis [34].
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1.3.3 The 2-5A system
The 2-5A system is an RNA degradation pathway that can be induced by IFNs. The
system consists of two IFN-inducible enzymes: 2-5A synthetase (OAS) and RNase L
[35]

. IFNs interact with cell surface receptors to activate a set of genes through the

JAK-STATs signal transduction pathway, some of which encode several 2-5 A
synthetases that are dsRNA dependent. In general, dsRNA is produced during viral
infection. DsRNA activates 2-5 A synthetases that can use intracellular ATP to
synthesize 2-5A that is a unique group of heat-stable, 5’-phosphorylated, 2’-5’phosphodiester-linked oligoadenylates, with general formula ppp(A2'p5')nA (n≥2).
The 2’- 5’ phosphodiester linkage is unusual in contrast to the typical 3’- 5’ linkage
present in RNA and DNA chains. 2-5A binds RNase L with high affinity, converting
it from its inactive, monomeric state to a potent dimeric endoribonuclease, thus
leading to the interruption of many fundamental processes which are essential for cell
function and virus replication (Figure 1-6). Cells over expressing RNase L overcome
viral infection, while over expression of a dominant mutant of RNase L results in an
increase of the susceptibility to viral infection. The role of 2-5 A system as a host
defense against some types of viruses is well established, but additional possible
biological roles of the 2-5A system, such as in cell growth and differentiation, heat
shock, atherosclerotic plaque, pathogenesis of type I diabetes, and apoptosis were also
reported [36].
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1.4A 2-5A Synthetase (OAS)
OAS activity has been demonstrated to be present in cells from mouse to humans,
even in reptiles and several avian species. OAs catalyzes the following reaction:

A number of growth factors can induce the expression of OAS.

Epidermal growth

factor can induce a 3-to 5-fold increase of OAS in human fibroblastomas, while
PDGF induces OAS in murine BALB/c3T3 cells. NGF increases the expression of
OAS from 5- to 25- folds in the rat pheochromocytoma cell line (PC12)

[37]

. Cyclic

AMP also enhances the OAS mRNA at the transcriptional level [38]. IFN-α, IFN-β and
IFN-γ all are able to induce an increase in OAS activity. Interestingly it has been
found that a given IFN subtype can differentially induce specific isoforms of OAS. In
Hs294t melanoma cells, after treatment with IFN-α, the isoform p40 was induced to
twice the extent of p100 [39]. In contrast, IFN-γ induced both isoforms equally. The
induction of p69 and p100 isoforms by IFN-γ has been studied in Daudi, fibroblast,
and colon adenocarcinoma cells in vitro and in vivo and there were significant
differences in induction between cell types [40]. The OAS activity has been found in a
variety of cell types during differentiation. Differentiation of skeletal muscle cells in
several species has been found to be associated with OAS induction and 2-5A
formation. Cell differentiation induced by chemicals or cytokines has been associated
with an increase of the OAS level. A 27-fold increase in the expression of OAS was
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observed in human HL-60 cells after treatment with dimethyl sulfoxide [41]. Induction
of differentiation in U937 cells by hydroxyvitamin D3 was associated with IFN
production and an increase in OAS

[42]

. On the other hand, OAS activity has been

found to be low in normal proliferating diploid Syrian hamster (FC13) cells [43]. Taken
together, all suggest a role of OAS in the anti-proliferative effects of IFN. Levels of
OAS depend also on a phase of the cell cycle. Using mouse embryo tertiary
fibroblasts progressing synchronously through the cell cycle as determined by
fluorescence-activating cell sorting, OAS levels were found to be low in quiescent
cultures, as well as during G1 and early S. They then rose 10-fold in late S and
decreased sharply in G2

[44]

. A similar, though quantitatively a lower pattern, was

found for RNase L. High OAS levels result in the inhibition of EMCV, mengovirus,
and vaccinia replication. Mammalian OAS is an important mediator of the antiviral
activity of IFNs. The existence of distinct 69- and 100-kDa forms of OAS, in addition
to the smaller (40 and 46 kDa) forms, has been established. Both human and mouse
2-5A synthetase gene families encode four forms of enzymes. The human p40-46
forms are coded for by 1.6 and 1.8 kb mRNAs, which are derived from the same gene
through cell type-specific differential splicing between the 7th and an additional 8th
exon of this gene, which is localized to chromosome 12

[45]

. The p40 and p46 OAS

isoforms are localized in nuclei. p69 OAS was localized in cytoplasm but it was found
in closer association with the nuclear membrane
[36]

[46]

. P100 is localized in cytoplasm

. Interestingly, OAs is persistently activated in patients with type 1 diabetes,

suggesting the involvement of the 2-5A system in the disease [47].
17

1.4B RNase L
RNase L is a unique ribonuclease because it requires an unusual allosteric effector,
2-5A, to catalyze the cleavage of single-stranded RNA [15]. 2-5A was discovered [48]
in extracts of IFN treated cells in the presence of dsRNA and ATP [49]. RNase L is
found in mammalian cells from mouse to humans, but not in fish, insects, plants and
bacteria

[50]

. In mice, RNase L is highly expressed in the spleen, lung, liver, and

kidney at 5 days of age and then decrease with age, except in the spleen where it
remains high until adulthood [51]. RNase L is localized in the nuclei and cytoplasm [52].
Its levels were found to be elevated during cell differentiation, as well as in growth
arrested cells
[54]

[53]

. Additionally, introduction of 2-5A into cells impaired cell growth

. Surprisingly, the increased RNase L levels were found in colorectal cancer tissues

although its role in the pathogenesis of this disease is largely unknown
and murine RNase L has been successfully cloned

[[22]]

[55]

. Human

. Many computer-assisted

homology searches, deletion analysis and site directed mutagenesis revealed the
structural and functional domains of RNase L (Figure 1-7). RNase L consists of three
domains, namely the N-terminal ankyrin domain, the protein kinase homology
domain, and the C-terminal ribonuclease domain. The N-terminal ankyrin repeat
domain, a region containing nine ankyrin-like macromolecular recognition repeats
(the ninth ankyrin repeat is incomplete), is responsible for 2-5A binding, and the
C-terminal domain is responsible for catalytic activity [56].
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B.1 Structure of 2-5A dependent RNase L
A successful molecular cloning of murine and human RNase L by Zhou and Hassel [57]
opened the door to the structural analysis of the enzyme. The sequence of full-length
human RNase L was obtained from a composite cDNA (HZB1) genomic construct.
Human RNase L gene encodes a sequence of 741 amino acids (m.w. 83,539 kDa)
with unique structural and functional motifs (Figure. 1-7). In the presence of 2-5A
activators, RNase L dimerizes to form catalytically active enzyme

[58]

. There are a

group of negatively charged amino acids from positions 451-459 and a positively
charged group at 677-684, and the composition of human RNase L is greater than
one-third charged amino acid residues with 113 aspartic acids plus glutamic acids and
arginine plus lysines; however the significance of the charge distribution is unknown.
A bipartite model for the structure of RNase L emerged in which the regulatory
functions of the molecule are located in the N-terminal half, whereas the catalytic
domain is present in the C-terminal half [59]. RNase L contains:

Ankyrin repeats
The analysis of the sequence of RNase L revealed that N-terminal 330 residues
contained 9 ankyrin (ANK) repeats, with an average length of 33 residues with 35%
sequence homology to human erythrocyte ANK

[58]

. The ninth ankyrin repeat is

incomplete. It has been reported that the crystal structure of the N-terminal ankyrin
repeat domain (ANK) of human RNase L is associated with the 2-5A binding

[56]

.

This finding was the first structural view of an ankyrin repeat structure directly
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interacting with a nucleic acid, rather than with a protein. According to the paper, the
ANK domain folds into eight ankyrin repeat elements and forms an extended curved
structure with a groove running across the long concave surface. Each repeat is
formed by ~33 amino-acid residues and consists of pairs of antiparallel α-helices
stacked side by side, which are connected by a series of intervening β-hairpin motifs.
The 2-5A molecule is accommodated at a concave site and directly interacts with
ankyrin repeats 2–4. The structural basis for 2-5A recognition by ANK is essential for
designing stable 2-5A with a high likelihood of activating RNase L. It is believed that
2-5A binding could induce a conformation change in the enzyme that releases an
internal clamp on the catalytic domain imposed by ankyrin repeats. Presumably, 2-5A
binding could result in the unmasking of an interaction domain, permitting
dimerization and activation of RNase L [35]. Fluorescence spectra of RNase L showed
clear difference in the presence and absence of 2-5A

[60]

. The alterations in spectra

supported conformation changes of the protein. Time-resolved anisotropy
measurements indicated that 2-5A binding led to a significant decrease in the
rotational radius of the protein. In addition, 2-5A provides the domain with resistance
to protease digestion as a result to conformational change. These results indicate that
the ankyrin-repeat domain of RNase L constricts its structure by binding of 2-5A [60].
Ankyrin repeats are highly conserved protein/protein interaction domains, that are
present in the amino-terminal half of the enzyme. Proteins that contain ankyrin
repeats function in transcriptional control, cell cycle regulation, and differentiation [61],
but the function of these repeats in RNase L has never been addressed, although a
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controlling role of them in dimerization and activation of the enzyme has been
suggested [57]. RNase L is the only nuclease known to contain ankyrin repeats.

Duplicated P-loop-like motif
Duplicated P-loop-like motif (GLY-LYS-THR) was implicated in mediating 2- 5A
binding [57]. Two P-loop motifs have been localized between amino acids 218 and 294.
Substitution of both lysines in p-loop, at position 240 and 274, with aspargines
diminished the binding ability for 2-5A [59]. The result suggested that lysines played a
crucial role in the sequence and they were considered the key amino acids that
interacted with phosphate groups of nucleotides. Ankyrin repeats 7th and 8th were
implicated in 2-5A binding until it was established

[56]

that 2nd and 4th ankyrin

repeats were responsible for the binding according to its crystal structure. RNase L
interacts in vivo with RLI protein, its inhibitor that does not show any significant
homologies with RNase L except that both proteins contain two P-loop motifs. The
RLI gene was localized to locus 4q31 by in situ hybridization indicating that this gene
and other enzymes of the 2-5A pathway are not organized in cluster in the human
genome [62]. RLI cDNA codes a 68-kDa polypeptide which expression is not regulated
by IFN [63].
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B.1.3 Cysteine rich region within a protein kinase homology is in the C-terminal half
of the enzyme but its kinase activity has never been detected. On the basis of a
computer-assisted analysis, it was proposed that RNase L was a functional active
protein kinase because it matches 11 typical protein kinase domains

[64]

. However,

some of the proposed protein kinase domains in RNase L are either incomplete or
differ significantly from known protein kinase domains. It is believed that RNase L
has significant homology in its C-terminal half with protein kinase domains VI and
VII and some additional homology to other protein kinase domains, especially with
domain II [35]. It would appear that RNase L is evolved, at least in part, from a protein
kinase. The similarity is due to evolutionary convergence to gain functions in
common with protein kinases, such as ATP binding activity [57]. In protein kinases, the
conserved lysine in domain II functions in binding to the α- and β- phosphoryl groups
of ATP and the conserved aspartate in domain VII chelates Mg2+ complexed with
ATP

[35]

. Both of these amino acids present in the protein kinase homology region of

RNase L as well. Within the protein kinase homology region of RNase L a
high-cysteine-content region is present [57]. Residues 401-436 in human RNase L, and
residues 395-444 in murine RNase L, bear resemblances to some zinc fingers,
protein/nucleic acid-binding domains

[65]

, suggesting a role in RNA binding. Because

zinc is known to inhibit the catalytic activity of RNase L, it is difficult to explain the
function of the cysteine-rich region

[58]

. On the basis of deletion-mutant analysis

[59]

,

the region between Glu711 and His 720 was revealed to be essential for RNA binding.
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Scanning mutagenesis examination indicated that both Tyr 712 and Phe 716 provide
the enzyme with a RNA binding activity [66].

B.2 Localization of the RNase L gene
The gene for RNase L, designated RNS4, maps to human chromosome 1q25 by
fluorescence in situ hybridization
breast cancer cells, and
carcinomas [68,

69]

[67]

, that is deleted or rearranged in prostate and

some gastric adenocarcinomas and oral squamous cell

.

B.3 RNase L antiviral activity
The classical IFN-dependent antiviral response to viral infection involves the
regulation of IFN-stimulated genes (ISGs), one being the gene encoding cellular
endoribonuclease RNase L, which inhibits protein synthesis and induces apoptosis by
cleaving rRNA

[70]

activity of IFN

[16]

. Considerable evidence exists relating RNase L to the antiviral
. EMCV, a cardiovirus, that is a member of Picornaviruses and

causes mild febrile illness in a number of species, including humans, has been often
evaluated in conjunction with the 2-5A system. Accumulation of 2-5A as measured
by rRNA cleavage has been observed in EMCV- and IFN- treated cells and the
observed elevation of 2-5A provides direct evidence for the activation of OAS by
viral dsRNA and the RNase L involvement in RNA degradation
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[71]

. Increased levels

of resistance to EMCV infection occurred in human glioblastoma T98G cells stably
transfected with a human OAS cDNA, which resulted in constitutive OAS production
[72]

. In other similar studies, transfection of murine cDNAs encoding the 43-kDa OAS

into NIH 3T3 cells results in varying levels of constitutive OAS production, as well as
greatly increased resistance to EMCV infection

[73]

. It has been reported that the

antiviral effect of IFN-α/β for EMCV was reduced by 250-fold when expression of
the SVT2/ZB1 mutant prevented 2-5A-dependent rRNA cleavage

[74]

. After RNase L

was truncated by 89 C-terminal aminoacid residues, its catalytic activity was
completely absent in stably expressed murine SVT2 cells and it resulted in inhibition
of the 2-5A system. A number of studies have found an increase of 2-5A levels,
activation of RNase L and characteristic rRNA breakdown in vaccine-virus infected,
IFN-treated cells [75].

The induction of an antiviral state by type I IFNs was evaluated in primary trigeminal
ganglion cells using herpes simplex virus type 1 (HSV-1). The cells treated with
mouse IFN-β showed the greatest resistance to HSV-1 infection. In the cells treated
with IFN-α and IFN-β, suppression of HSV-1 replication occurred through an RNase
L dependent pathway

[76]

. Over expressed RNase L by >100-fold compared with

levels of the endogenous murine RNase L in 3T3/pLZ suppressed the replication of
diverse viruses: EMCV, vesicular stomatitis virus, human parainfluenza virus-3, and
vaccinia virus. Additional reductions in viral growth were obtained by treating
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3T3/pLZ cells with IFN (alpha + beta) before infections. These results directly
demonstrate the anticellular and antiviral potential of the 2-5A system
system is also active in the cells with HIV infection

[78]

[77]

. The 2-5A

. The HIV-1 gene product tat

causes a dramatic increase in the steady-state levels of HIV-1 long terminal repeat
(LTR)-derived mRNAs. The interaction of tat with a region in the HIV LTR called
TAR mediates this up-regulation of HIV mRNAs but the TAR RNA sequence
activates OAS [79]. The expression of vector containing OAS that was introduced into
coding region downstream of a 3’-LTR of HIV-1 was activated by the HIV tat protein.
Apparently through the tat-mediated trans-activation of OAS, resulting in an increase
of 2-5A oligonucleotides, the replication of HIV was inhibited in cells transfected
with the vector. It has been

[80]

postulated that HIV-trans–activated OAS could block

HIV replication, leading to design a possible therapeutic approach that may be used to
treat AIDS. To determine the involvement of RNase L in the control of human
immunodeficiency virus type 1 (HIV-1) replication, a segment of the HIV-1 nef gene
was replaced with human RNase L cDNA. HIV-1 provirus containing sense
orientation RNase L cDNA increased expression of RNase L, resulting in 500- to
1000-folds inhibition of virus replication in Jurkat cells for about 2 weeks

[81]

.

Subsequently, a partial deletion of the RNase L cDNA resulted in an increase of virus
production. The anti-HIV activity of RNase L correlated with a decrease of HIV-1
RNA along with acceleration in cell death accompanied by DNA fragmentation. The
findings demonstrate that RNase L impairs HIV replication.

25

B.4 The potential role of RNase l in the immune system
RNase L is present at constitutive basal levels in most mammalian cells and is
induced by IFNs, especially in mouse cells

[57]

. There are remarkable differences of

RNase L levels in different tissues. High levels of RNase L expression were found in
the spleen and the thymus, which implicates that the enzyme may play a role in the
immune system. Mice with targeted disruption of RNase L have enlarged thymuses
containing excess numbers of thymocytes, implicating that RNase L may be involved
in T-cell development [35]. Furthermore, the immune response to DNA-based vaccine
[82]

and suppression of skin allograft rejection are impaired in RNase L null mice

suggesting that RNase L plays a role in immune responses. It has been reported

[83]

,

[84]

that RNase L is involved in activation of p-38 MAPK and JNK by dsRNA and EMCV.
The consequence of the activation of these pathways is the production of
pro-inflammatory and pyrogenic cytokines, such as IL-1β, IL-6, TNF-α, and INF-γ
which promotes immune responses.

B.5 RNase L is a tumor suppressor
Over-expression of RNase L in NIH 3T3 cells markedly enhances the antiproliferative
function of IFN, whereas the dominant-negative RNase L suppresses the
anti-proliferative activity of IFN in SVT2 cells

[74]

. The 2-5 A/RNase L system

contributes to apoptosis of viral infected cells by both degrading cellular RNA and
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blocking anti-apoptotic proteins such as Bcl-2 [75]. Proapoptotic function of RNase L
may limit some diseases such as prostate cancer. Several studies linked the hereditary
prostate cancer 1 (HPC1) allele to the RNase L gene

[85,86,87]

located at chromosome

1q25, a region deleted or rearranged in some breast cancers. The studies suggest that
mutations in RNASEL predispose men to an increased incidence of prostate cancer.
The RNase activities of missense variants of human RNase L were compared after
expression in a mouse RNase L -/- cell line. Several variants (G59S, I97L, I220V,
322F, Y529C, and D541E) produced similar levels of RNase L activity as a wild-type
enzyme, but the R462Q variant, previously implicated in up to 13% of unselected
prostate cancer cases, bound 2- 5A at wild-type levels but had a 3-folds decrease in
RNase L activity. The deficiency in RNase L (R462Q) activity was correlated with a
reduction in its ability to dimerize into a catalytically active form. Furthermore, the
RNase L mutant (R462Q) was defective in causing apoptosis in response to 2-5A
consistent with its possible role in prostate cancer development. It has been proposed
[89]

that RNase L functions as a tumor suppressor on the basis of its ability to degrade

RNA, thus initiating a cellular stress response that leads to apoptosis. The anti-tumor
activity of RNase L can be induced by a small molecule, 2-5A. Indeed, 2-5A
activation of RNase L produces a remarkable stimulation of transcription (>/=20-fold)
for genes that suppress virus replication and prostate cancer

[ 88 ]

. Among the

2-5A-induced genes are several IFN-stimulated genes, including IFN-inducible
transcript 1/P56, IFN-inducible transcript 2/P54, IL-8, and IFN-stimulated gene 15.
2-5A

also

potently

elevated

the

expression
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of

macrophage

inhibitory

cytokine-1/nonsteroidal

antiinflammatory

drug-activated

gene-1,

a

TGF-beta

superfamily member implicated as an apoptotic suppressor of prostate cancer.
Transcriptional signaling to the macrophage inhibitory cytokine-1/nonsteroidal
anti-inflammatory drug-activated gene-1 promoter was deficient in HeLa cells
expressing a nuclease-dead mutant of RNase L, which was JNK and ERK dependent,
and both were activated in response to 2-5A treatment. These findings suggest that
activation of RNase L by 2-5A may produce antitumor response as demonstrated in a
mouse model of prostate cancer [89]. 2-5A also induces apoptosis in prostate cancer
cells. The androgen receptor and RNase L interact in a ligand dependent manner,
which may be associated with prostate cancer initiation and progression

[ 90 ]

.

Furthermore, overexpression of wild type RNase L conferred IFN sensitivity to a
dihydrotestosterone inducible reporter gene, whereas R462Q-mutated RNase L is
unable. It is suggested that RNASEL variants Glu265X and Arg462Gln might
contribute to the tumorigenesis of sporadic and familial pancreatic cancer [91].

B.6 RNase L plays a role in the regulation of gene expression
Documented evidence has shown that RNase L plays an important role in the
regulation of the stability of several gene products such as ISG43, ISG15 [92], PKR [93],
MyoD mRNA in myocytes

[94]

and mitochondrial mRNAs in H9 lymphocytes

[95]

.

ISG43 expression was negatively regulated by RNase L in IFN-treated cells. ISG43
induction is a primary response to IFN treatment and requires a functional JAK/STAT
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signaling pathway. The kinetics of ISG43 induction was identical in wild type and
RNase L-knockout fibroblasts; however, the decline in ISG43 mRNA following IFN
treatment was markedly attenuated in RNase L-knockout fibroblasts. The delayed
shut-off kinetics of ISG43 mRNA corresponded to an increase in its half-life in
RNase L-deficient cells. ISG15 mRNA also displayed RNase L-dependent regulation.
These findings show a novel role for the 2-5A system in the attenuation of the IFN
response [92].

The role of RNase L in the transient control of the IFN response was also suggested
[96]

. Khalid et al. found that ectopic expression of RNase L prevented the IFN

induction of PKR. After RNase L-null cells were treated with IFN-α, PKR induction
was increased and PKR mRNA stability was enhanced as well. In addition, the
phosphorylated form of eIF2α appeared with extended kinetics compared with that in
similarly treated wild type cells. An enhanced IFN response in RNase L-null cells was
also demonstrated by monitoring inhibition of viral protein synthesis. The role of
RNase L and RLI in muscle differentiation was determined by transfection of C2
mouse myoblasts with sense and antisense RLI cDNA constructs [94]. Importantly, the
over expression of RLI in C2 cells was able to inhibit RNase L activity, as a result, an
increased level of MyoD mRNA was observed, leading to accelerate kinetics of
muscle differentiation. Inversely, transfection of an RLI antisense construct resulted
in increased RNase L activity, reduced MyoD mRNA production, and delayed
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differentiation. Consistent with these observations, MyoD mRNA levels were also
decreased in C2 cells transfected with an inducible RNase L construct. Therefore,
these data suggest that RNase L is directly involved in myoblast differentiation,
probably through its role in regulating MyoD stability. In addition, RNase L in also
found to interact with eRF3/GSPT1, a human translation termination factor, to
regulate the expression of a gene at its translational level [97].

1.4C 2’-5’-phosphodiesterase
2’-5’-phosphodiesterase (2’-PDE) is the third enzyme of the 2-5A system. The
recombinant human 2'-PDE expressed in mammalian cells cleaves the 2'-5’
phosphodiester bond of 2-5A analogs, leading to destruction of 2-5A in the cells

[98]

.

No sequences with high homology to this human 2'-PDE are found, so it is considered
to be a unique enzyme without isoforms. Suppression of 2'-PDE by a small interfering
RNA and a 2'-PDE inhibitor resulted in significant reduction of viral replication,
whereas overexpression of 2'-PDE protected cells from IFN-induced antiproliferative
activity. These observations identify 2'-PDE as a key regulator of the 2-5A system
and as a potential novel target for antiviral and antitumor treatments

[98]

. The activity

of the 2'-5' phosphodiesterase is very high in quiescent cells while the levels of OAS
and RNase L are high at the end of S phase [99].

30

Figure 1-7. The structure of RNase L.

(Chakrabarti A, Jha BK, Silverman RH. J

Interferon Cytokine Res. 2011)
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1.5 Our hypothesis
These observations implicate that RNase L may play an important role in the immune
system. Indeed, studies have revealed that skin allograft rejection is suppressed in
mice lacking RNase L, suggesting the involvement of RNase L in T cell immunity,
particularly CD4+ T cell mediated immunity

[100]

. In addition, alphavirus-based DNA

vaccination against a non-mutated tumor-associate self-antigen (tyrosinase-related
protein-1, TRP-1) is severely impaired in RNase L null mice, indicating that RNase L
plays an important role in host immune system against cancer [101].
In this study, we present evidence showing that RNase L may be involved in the
pathogenesis of type I diabetes. RNase L deficient RIP-B7.1 mice significantly
delayed the onset of diabetes induced by STZ and poly I:C. Immunohistostaining
revealed that the population of infiltrated CD8+ T cells was remarkably reduced in the
islets of RNase L deficient mice, implicating RNase L may contribute to type I
diabetes onset through mediating the infiltration of immune cells. Furthermore, RNase
L regulated the expression of certain proinflammatory genes in the pancreas under the
special condition. Our results suggest a novel role of RNase L in the development of
type I diabetes.
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PROJECT II:
DEVELOPMENT OF QUANTITATIVE LC-MS/MS
METHODS FOR THE PHARMACOLOGICAL
STUDIES OF ANTI-CANCER DRUG
CANDIDATES
1.7 Overview of 6-hydroximino-4-aza-A-homo-cholest-3-one
The synthesis of some aza-homosteroid compounds with unusual and interesting
structures has been reported recently

[1-4]

(Figure 1-8). These compounds exhibit

valuable biological activities such as cytotoxicity and antibacteria. Study of
aza-homosteroids indicates that the presence of the characteristic group (-NH-CO-) in
the aza-homosteroid molecule has been demonstrated to be important in lowering
toxicity and improving anti-tumor activity of the compounds in cancer treatment [5].

It

was

reported

that

6-hydroximino-4-aza-A-homo-cholest-3-one

6-hydroxyl-4-aza-A-homo-cholest-3-one

(Figure

1-9),

new

steroidal

and
lactams

displayed antiproliferative activity against some cancer cells through inducing cancer
cell apoptosis by activation of the intrinsic pathway. The apoptotic function of the
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compounds was demonstrated by release of cytochrome C, activation of caspase 3 and
annexin V labeling. Furthermore, the compound was able to inhibit tumor growth in
an athymic mouse model. (Table 1-1)

Figure 1-8. Steroidal derivatives

Figure 1-9. The structure of 6-hydroximino-4-aza-A-homo-cholest-3-one

Table 1-1. In vitro anti-tumor activities (IC50 in µmol /L) of the compounds

Carcinoma Cell Lines

Compound
GNE 2

SPC-A

Tu 686

PC-3

HT-29

1

12.1

74.5

24.9

14.5

10.6

2

15.8

35.3

31.2

18.3

15.5
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1.8 Pharmacological studies of anti-cancer drug candidates
The monitoring of anticancer drugs in biological fluids and tissues is important during
both pre-clinical and clinical development and often in routine clinical use.
Traditionally, liquid chromatography (LC) in combination with ultraviolet (UV),
fluorescence, or electrochemical detection is employed for this purpose. The
successful hyphenation of LC and mass spectrometry (MS), however, has
dramatically changed this. MS detection provides better sensitivity and selectivity
than UV detection and, in addition, is applicable to a significantly larger group of
compounds than fluorescence or electrochemical detection. Therefore, LC-MS has
now become the method of first choice for the quantitative bioanalysis of many
anticancer agents. There are still, however, a lot of new developments to be expected
in this area, such as the introduction of more sensitive and robust mass spectrometers,
high-throughput analyses, and further optimization of the coupled LC systems. Many
articles have appeared in this field in recent years. In this study, we use LC-MS as a
powerful tool for the quantitative analysis of anticancer drugs in biological samples.

The efficacy and toxicity of many anticancer drugs are related to parent drug and/or
metabolite concentrations in body fluids and tissues. Therefore, during both
pre-clinical

and

clinical

drug

development,

profound

knowledge

of

the

pharmacokinetic properties (absorption-distribution-metabolism-elimination; ADME)
of the drug is essential. Furthermore, since anticancer agents often have narrow
48

therapeutic ranges and inter-and intra-patient variability in pharmacokinetic properties
are high, drug monitoring in routine clinical use may be required for safe and
efficacious therapeutic use

[1]

. Traditionally, liquid chromatography (LC) has been

employed for this purpose. Since most anticancer agents are non-volatile,
thermolabile, and polar compounds, they are usually not amendable to gas
chromatography (GC). LC-detection involves predominantly ultraviolet (UV),
fluorescence, or electrochemical detection. UV detection, however, is not very
sensitive and suffers from low specificity, while fluorescence and electrochemical
detection, although more sensitive and specific than UV detection, are limited to
compounds with fluorescent or electro-active groups or do otherwise require
derivatization. Quantitative detection of small molecules by mass spectrometry (MS),
off-line LC-MS for qualitative analysis and on-line GC-MS has been common
practice for many years. On-line LC-MS for quantitation purposes, on the other hand,
was complicated until the introduction of atmospheric pressure ionization (API)
techniques (e.g. atmospheric pressure chemical ionization (APCI) and electrospray
ionization (ESI)) in the 1980s. In recent years LC-MS interfaces have further
improved, mainly because techniques such as ionspray (ISP; pneumatically assisted
ESI), turbo-ionspray (TISP; pneumatically assisted ESI with an additional hot drying
gas perpendicular to the spray), and heated nebulizer (HN)-APCI (pneumatically
assisted APCI) became available that facilitate the evaporation of LC solvents.
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1.9 Quantitative LC-MS/MS method development
1.9.1 High Performance Liquid Chromatography (HPLC)
Chromatography is a physico-chemical separation method: a dissolved substance
mixture is piped by a mobile phase (gas or liquid stream) through a stationary phase.
The separation is based on the different physical and chemical characteristics of the
single components in the substance mixture. Today High-performance liquid
chromatography is one of the most used analytical separation techniques, because of
its sensitivity, its adaptability to accurate quantitative determinations, its suitability for
separating non-volatile species or thermally fragile ones, and its widespread
applicability to substances that are of interest in industry and science [6].

1.9.2 Chromatographic working principles
The chromatographic separation starts by applying the sample in the column. The
different components move depending on the elution method with different velocities
through the column and are detected at the end of the column. The result is a
chromatogram which shows the peaks of the different components in dependence to
the time, when the substances left the column and are detected. The time needed for
the way from the injection to the exit of the column is called dead time. Through
interactions between the sample components and the stationary phase the elution of
the components is slowed down (Figure 1-10), described by the retention time. The
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peaks are also characterized by their peak width, full width at half maximum, peak
height, and peak area. Under optimal circumstances the peaks are slim and symmetric.
But dispersion effects are responsible for peak broadening. So the shape of the peak
gives information about the quality of the separation of the column. Peak shapes with
variations on the increasing (fronting) or decreasing side (tailing) indicate
inhomogeneity or separation problems. Homogeneous peaks should be slim and
regular [7].

Figure 1-10. Schematic illustration of a chromatogram
“High Performance Liquid Chromatography” is a particular kind of column
chromatography. The system consists of a device that pumps the mobile phase, an
injector to apply the sample, a column and a detector.

The separation efficiency of the column is dependent on the particle diameter and the
pore size of the particles. Due to this separation efficiency the development of HPLC
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as separation process is possible. The smaller the particle sizes and the more
homogeneously the particle size distribution of the stationary phase in the column, the
higher is the separation performance. But the small particle sizes lead to a high
packing density of the stationary phase. Now the force of gravity is not enough
anymore for the transport of the mobile phase. Therefore the mobile phase has to be
pumped through the column with special HPLC pumps. These pumps supply flow
rates from 0.1 ¨C 10 mL/min and pressures up to 400 bars.

a. Stationary Phase
Basically, besides silica gel and its modifications, all stationary phases used in column
chromatography can be also used in HPLC. In the pharmaceutical sector the most
important stationary phase today is the C-18 reversed phase (Table 1-2)
Table 1-2. Stationary Phases used in HPLC
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b. Mobile Phase
The mobile phase transports the substances through the column. Hydrophilic solvents
have a high elution force with polar stationary phases, lipophilic solvents have a high
elution force with reversed phases. In the so-called eluotropic row, solvents are
classified according to their elution force, for example:

1.9.3 Reversed-phase chromatography (RPC)
In reversed phase chromatography the stationary phase is nonpolar and is called
“reversed Phase”. The stationary phases are, for example, silica gels modified with
lipophilic groups like alkyl-, phenyl- or cyclohexylrests. As mobile phase
methanol-water or acetonitrilewater mixtures with appropriate additives (buffer, acids)
are often used [4]. The choice of the mobile phase is dependent on the characteristics
of the substance, which is examined, and the stationary phase. The elution of
substances on a particular stationary phase can be controlled through the composition
of the mobile phase. The mobile phases used for HPLC have to be very pure and
should be degassed before use. The separation performance of the system is also
dependent on the elution velocity. Too small or too high flow rates impair the
separation.
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1.9.4 Detectors
The substances arrive at the detector after they have passed the separation column.
The detection of the substances is an important prerequisite for the proof and the
quantification of analyzed components. So the detector should have a high sensitivity
for to be determined substances. These detectors are UV/VIS detectors, fluorescence
detectors, electrochemical detectors, conductivity detectors and mass selective
detectors (mass spectrometry). The interconnection of a HPLC system with a mass
spectrometer is the most elaborate detection process in HPLC. The HPLC system is
connected with the mass spectrometer by a special interface. The substances separated
by HPLC are evaporated and ionized in the interface and brought into the mass
spectrometer where they are analyzed [4].
Table 1-3. Typical Chromtographic characteristics for analytical HPLC application [8]
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1.10 Mass spectrometry (MS)
Mass spectrometry is an analytical technique used to determine the molecular mass of
free ions in a high vacuum. A mass spectrometer is comprised of an ion source, in
which gaseous ions are formed, a mass analyzer, which separates the ions with respect
to their mass to the charge ratio (m/z) and a detector that measures the ion flow. As a
result, a mass spectrum is generated in which the relative frequencies of the ions are
plotted against their m/z ratios. The ionization of the analytes can either be made by
uptake or loss of an electron or a proton. This is, for instance, reached by bombarding
the sample with electrons (electron impact ionization, EI), with atoms or ions (fast
atom bombardment (FAB) ionization) or with photons (laser desorption/ionization,
LDI). For polar, non-volatile molecules it is possible to do the ionization of the
dissolved sample in an electric field (electrospray ionization, ESI) or from the solid
phase by means of matrix-assisted laser desorption/ionization (MALDI). For the
separation and the detection of analyte ions there are several analyzers with
appropriate detectors. The separation of the ions can be effected:
a. By the combination of a magnetic field with an electric field (sector
instruments)
b. In the high-frequency field of a quadrupole system (quadrupole instruments)
c. According to their flight time in a test tube in conjunction with a pulsed ion
generation (time-of-flight, TOF, instruments).
Ions can also be collected in an electric ion trap (ion trap) or magnetic ion trap (ion
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cyclotron resonance cell ICR) followed by mass analysis of characteristic resonance
frequencies.

1.10.1 Ion source
The connection of LC and MS is done by means of an ion source. The ion source has
not only the task to vaporize and ionize the analyte, but also to remove excessive
solvent from the HPLC to keep up the required high vacuum in the MS. In the present
work the ionization is done by Electro spray ionization (ESI) (Figure1-11).
Ionization principle:
In the electric field, the ions are transferred into the gas phase at atmospheric pressure.
This process consists of four steps:
a. Formation of small charged droplets of electrolyte solution.
b. Continuous loss of solvent by evaporation of these droplets, whereas the
charge density increases at the droplet surface.
c. Repeated spontaneous degradation of the droplets (Coulomb explosion).
d. Desolvation of the analyte at the transfer into the mass spectrometer.
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Figure 1-11. Principle of electrospray ionization
The ESI process begins with the continuous supply of dissolved analyte molecules to
the tip of a conductive capillary. The applied electric field between the capillary tip
and a mass spectrometer also penetrates the analyte solution and separates the ions.
For the detection of positively charged ions (positive mode), the positive ions are
pulled to the liquid surface. Accordingly, the negative ions are pushed in the opposite
direction until the electric field is withdrawn within the liquid through the
redistribution of negative and positive ions. The positive ions accumulated at the
liquid surface are further drawn towards the cathode. This produces a characteristic
liquid cone (Taylor cone), because the surface tension of the liquid counteracts the
electric field. In the sufficiently high electric field the cone is stable and is released
from the tip, a continuous filament-like liquid flow with a few millimeters in diameter.
At some distance from the anode this liquid flow becomes unstable and is divided into
tiny droplets. The surface of the droplets is enriched with positive charges. Since there
are no negative counter ions anymore, there is a positive net charge. The first formed
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droplets have a diameter of a few micrometers and have a high charge density (about
105 charges per droplet). These droplets are close to the stability limit (Rayleigh limit)
concerning their composition, size and charge. This stability limit is determined by
the repulsive Coulomb force of same charges and the cohesive surface tension of the
solvent. The Rayleigh equation [9] indicates when the charge Q is equal to the surface
tension γ:

By the evaporation of the solvent and at constant charge Q, the droplets shrink until
the radius exceeds the Rayleigh limit. Now the droplets break through the repulsion of
the same charges in many small droplets of a few nanometers in diameter (Coulomb
explosion). The last step of the ESI process is the evaporation of the rest of the
solvent and the transfer of the produced ions into the mass spectrometer [7].

1.10.2 Mass analyzer
The produced ions are analyzed with a mass analyzer. It scans the ions and puts out a
mass spectrum, in which the detected masses and the corresponding retention times
are shown. The higher the detected peak is, the more ions of the same mass are in the
sample. Usually two connected mass analyzers are used to achieve a lower detection
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limit and a higher selectivity. Between these two mass analyzers there is a collision
chamber in which the mother ions are fragmented into smaller pieces. With this
tandem mass spectrometry individual components can be detected specifically within
a complex mixture. The most frequently used mass analyzers are the triple quadrupole
and the quadrupole ion trap mass analyzers.

1.10.3 Tandem mass spectrometry
With triple quadrupole instruments (Figure 1-12), not only detailed information on the
mass but also on the structure of the ions can be obtained. The triple quadrupole mass
spectrometer consists of four quadrupoles Q0 to Q3 with two measuring quadrupoles
(Q1 and Q3). Q0 is a so-called assistant quadrupole which is operated with alternating
current. It focusses the generated ions and transfers them efficiently into the center of
the quadrupole field where they begin to oscillate. Q1 is the first measuring
quadrupole which scans the ions. Q2 is a collision chamber which can be filled with
gas (e.g. nitrogen). By collision with inert gas atoms, the ions coming out from Q1
fragment into Q2. The molecular weights of the resulting fragment ions are then
determined in quadrupole Q3. The triple quadrupole mass spectrometer can operate in
different modes of measurement.
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Figure 1-12. Composition of a Triple Quadrupole Mass spectrometer. (Applied
Biosystems 2001)
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CHAPTER II
INVESTIGATION OF THE CONTRIBUTION OF
RNASE L TO THE PATHOGENESIS OF TYPE I
DIABETES
2.1 Introduction
In this study, an RNase L deficient RIP-B7.1 mouse line was created which is more
vulnerable to environmentally harmful factors such as viral infection. The onset of
type I diabetes was found to be significantly delayed in these RNase L deficient
RIP-B7.1 mice induced by polyinosinic:polycytidylic acid (poly I:C), a type of
double-stranded RNA which is used to mimic viral infection, and Streptozotocin
(STZ), a drug which can artificially induce type I-like diabetes in experimental
animals. Immunohistostaining showed that the population of infiltrated CD8+ T-cells
was remarkably decreased in the islets of RNase L deficient mice after poly I:C
treatment, implicating RNase L contributing to type I diabetes onset by regulating
immune responses. Furthermore, RNase L was responsible for the expression of
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certain proinflammatory genes in the pancreas under the special condition. This
project provides new insight into the molecular mechanism leading to β-cells
destruction in diabetes.
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2.2 Reagents and Methods
2.2.1 Tissue Culture and treatment
NIH 3T3 cells, NIT-1 (ATCC) and mouse embryonic fibroblasts (MEF) were grown
in DMEM (Cleveland Clinic, OH) supplemented with 10% fetal bovine serum (PAA
Laboratories, MA) and antibiotics in a humidified atmosphere of 5% CO2 at 37oC. For
treatment, NIT-1 cells were grown to 90% confluence and incubated with 1,000 U/ml
murine IFN-α (R&D Systems) for 14 h. BMMs were generated from the bone
marrow cells of RNase L wild type and deficient C57BL/6 mice by using a
modification of a previously reported method [1].

2.2.2 Generation of an RNase L deficient C57BL/6.RIP-B7.1 mouse
An RNase L-/- mouse (C57BL/6) was cross-bred with a C57BL/6.RIP-B7.1 mouse
(Barbara Davis Center of Childhood Diabetes, University of Colorado Health
Sciences Center, CO). Genotyping for RNase L and B7.1 was performed by using
PCR with the condition: denaturing at 96oC for 4 min, for each cycle, denaturing at
96oC for 45 sec, annealing at 55oC for 45 sec, and extension at 72oC for 1.5 min, for
32 cycles, then an additional cycle at 72oC for 5 min. The pair of RNase L primers
was: 5’GCA TTG AGG ACC ATG GAG AC3’ and 5’GGA GGA GAA GCT TTA
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CAA GGT3’; for B7.1, the primers were: TGA AGC CAT GGG CCA CAC3’ and 5’
GGC TCC TTG TCG GCG TTC TA3’.

2.2.3 Diabetes induction
Six-week-old C57BL/6 RNase L deficient RIP-B7.1 and C57BL/6 RIP-B7.1 wild
type mice were injected intraperitoneally (i.p.) with poly I:C (Sigma, St. Louis, MO)
daily at a concentration of 5 µg/g body weight for 7 days, and then immunized
(i.p.)with 25 µg/mouse for insulin ( Eli Lilly, Indianapolis, IN) on day 14 after poly
I:C treatment. Blood glucose was measured weekly with the Glucose Oxidase
Reagent Set (Pointe Scientific, Canton, MI). Briefly, 10 µl of plasma was mixed with
1ml of the working reagent provided by the manufacturer and incubated at 37oC for
exactly 5 min. After incubation, the absorbance at 500 nm were read and recorded.
The mice were considered diabetic after two consecutive blood glucose values ≥250
mg/dl.

2.2.4 Immunohistostaining
The pancreas obtained from the mice was fixed in 10% formalin, paraffin embedded
and sectioned at 5µm, subsequently stained with hematoxylin and eosin. Pancreatic
sections were microscopically examined for infiltration of immune cells. The tissue
sections were stained with rat polyclonal antibodies against CD4, CD8, F4/80, CD11b
(eBioscience, San Diego, CA) and a monoclonal antibody to insulin (Abcam,
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Cambridge, MA), followed by incubating with a peroxidase anti-peroxidase antibody
(ICN, Costa Mesa, CA). Images were developed by using 3-3'-diaminobenzidine as a
chromogen (Dako, Carpinteria, CA).

2.2.5 Flow Cytometry
Single cell suspension from the spleens was stained with conjugated mAbs including
FITC-CD4, PE-CD8, FITC-IgD, PE-B220, APC-Gr.1, FITC-CD11b (BD Pharmingen,
San Jose, CA). Cell-associated fluorescence was analyzed with a FACScan instrument
and associated Winlist 5 software.

2.2.6 Western blot analysis
After treatment, cells were washed twice with ice-cold PBS and collected with a
scraper. The cytoplasmic extracts were prepared by suspension of the cell pellets in
the NP-40 lysis buffer (10 mM Tris-HCl, pH8.0, 5 mM Mg(OAc)2, 90 mM KCl, 0.2
mM PMSF, 100 units/ml aprotinin, 10 µg/ml leupeptin and 2% NP-40). After
centrifugation at 10,000 x g in a microcentrifuge at 4oC for 10 min, the cell extracts
(100 µg per sample) were fractionated on SDS-10% polyacrylamide gels and
transferred to PVDF membranes (Millipore, Billerica, MA). The membranes were
blocked with 5% nonfat milk in PBS containing 0.02% sodium azide and 0.2% (v/v)
Tween 20, and incubated with different primary antibodies for 1 h at room
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temperature. The membranes were then washed with PBS containing 0.2% (v/v)
Tween 20 and incubated with specific secondary antibodies conjugated with
horseradish peroxidase (Cell Signaling, Billerica, MA) for 1 h at room temperature.
After washing, the proteins were detected by a chemiluminescent method according to
the manufacturer’s specification (Pierce, Rockford, IL).

Pancreatic tissue extracts

obtained from mice (2/group) treated with or without poly I:C (Sigma, St. Louis, MO)
every other day at a concentration of 5 µg/g body weight for one week (three times)
were analyzed as described above.

2.2.7 Enzyme-linked immunosorbent assay (ELISA)
The expressing level of proinflammatory genes in the extracts of the pancreases was
measured by ELISA with commercial available kits (eBioscience, San Diego, CA and
R&D Systems, Minneapolis, MN).

Briefly, flat bottom 96-well ELISA plates were

coated with a capture antibody at 4°C according to manufacturer’s instruction.

After

overnight incubation at 4°C, the plates were washed three times and blocked with the
blocking buffer provided in the kit, and then incubated with standards and cell culture
medium samples for 2 h at room temperature. After washing the plates, a specific
biotinylated antibody was added to each well and incubated for 1 h, followed by
washing and 30 min incubation with avidin peroxidase. Then, substrates containing 3,
3' 5, 5'-tetramethylbenzidine (TMB) and hydrogen peroxide were added, and the
reaction was terminated by adding 50 µl of phosphoric acid after 30min.
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Plates were

read at 450nm in a 96-well LD 400C microplate reader (Beckman Coulter, Fullerton,
CA).

2.3 Results
2.3.1 IFN-α and poly I:C induced the expression of RNase L in the
tissues and cells
RNase L is expressed in nearly all types of mammalian cells from mouse to man

[23]

.

To examine the expressing level of RNase L in the pancreas, the tissue extracts of
eight different organs from a C57BL/6 mouse (Jackson Laboratory) were analyzed by
the 2-5A binding assay [30]. As shown in Figure 2-1A, there are remarkable tissue
differences in RNase L levels. High levels of RNase L expression were found in the
lung, spleen and thymus. However, the basic level of RNase L in the pancreas was
very low. Similar to our previous result, RNase L was found to be highly expressed in
primary immune cells (Figure 2-1B). This observation implicates a possible role of
RNase L in the immune system. To determine if IFN-α is able to induce the
expression of RNase L in pancreatic cells, NIT cells, a murine β-cell line, were
treated with IFN-α and the induction of RNase L was examined by Western blot
analysis. Obviously, the expression of RNase L was highly inducible in β-cells
(Figure 2-1C). Double stranded RNA such as poly I:C can be used to mimic viral
infection in vitro and in vivo.
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To determine if poly I:C is able to induce the up-regulation of RNase L expression in
the pancreas, mice were treated with or without poly I:C and the expression of RNase
L in the pancreatic tissue extracts was measured. Clearly, poly I:C was a potent
inducer of RNase L expression in the pancreas (Figure 2-1D).

A.

B.

C.

D.

Figure 2-1. The expressing levels of RNase L in the tissue extracts from eight organs
(A)

and immune cells (B). Sp-cells: primary splenocytes; BMM: bone

marrow-derived macrophages; NIH3T3: mouse fibroblasts; MEF: mouse embryonic
fibroblasts.

(C) IFN-α induces the expression of RNase L in NIT-1 cells. NIT-1

cells were treated with 1,000 units/ml of IFN-α for 16 h and RNase L in the cells was
determined by Western blot analysis. (D) Mice (2/group) treated with or without poly
I:C at a concentration of 5 µg/g body weight every other days for one week (three
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times) and the level of RNase L in the pancreatic tissue extract was determined by
Western blot analysis with a polyclonal antibody to mouse RNase L.

2.3.2 RNase L is associated with subclasses of immune cells in the spleen
Splenic cells, in particular B cells, play an important role in autoimmune diseases
such as systemic lupus erythematosus (SLE) and type I diabetes. To determine if
deficiency of RNase L impacts the subclasses of immune cells in the spleen, splenic
cells isolated from RNase L+/+ and -/- mice treated with or without either LPS or Poly
I:C were subjected to flow cytometry sorting based on cell surface markers. As shown
in Figure 2-2A, the population of CD4+/CD8+ T cells in the spleen of RNase L-/- mice
was 37% less than that in the spleen of RNase L+/+ mice, whereas the population of
the double labeled T cells was 72% less in the spleen of RNase L-/- mice compared to
that in RNase L+/+ mice after treatment with LPS. Similar to CD4+/CD8+ T cells, the
population of B220+/Ig D+ B cells in the spleen of RNase L -/- mice was 39% less than
that in the spleen of RNase L+/+ mice after LPS stimulation although the population of
B220+/Ig D+ B cells in the spleen of intact RNase L-/- mice was slight higher than that
in the spleen of RNase L+/+ mice under the same condition.

In contrast, the

population of Gr.1+/CD11b+ macrophages was almost doubled in the spleen of RNase
L-/- mice in compared to that in RNase L +/+ mice in the presence of LPS although the
ratio of these cell population in both type of untreated mice was nearly equal.
Interestingly, Poly I:C treatment increased the population of double labeled
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CD4+/CD8+ T cells by 46% in RNase L wild type mice, but no significant change in
the RNase L-/- mice. Similar to LPS treatment, the population of B220+/Ig D+ was
decreased by 45% after Poly I:C treatment in RNase L-/- mice whereas the double
labeled cells in Poly I:C treated RNase L+/+ mice were only slightly more than that in
untreated mice. However, the differential change of Gr.1+/CD11b+ cells after Poly I:C
treatment were very close although the percentile of the double labeled cells were
significantly increased compared to that in both types of intact mice. Taken together,
the results implicate that RNase L may be associated with developing the subclasses
of immune cells in the spleen.
A-1.
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Figure 2-2. Population of immune cells in the spleen

Six-week-old male RNase

L deficient and wild type mice (3mice/group) were treated with or without 25 µg LPS
or 5 µg/g body weight poly I:C for each mouse every other day for a week. The
splenic cells combined from three mice were subjected to cell sorting after labeled
with CD4, CD8, B220, Ig D, Gr.1 and CD11b alone or combined. A-1 and B-1:
CD4/CD8; A-2 and B-2: B220/Ig D; A-3 and B-3: Gr.1/CD11b.

2.3.3 Lack of RNase L delayed the onset of type I diabetes
Viral infection is believed to be a potent factor in triggering autoimmune responses in
the pancreas, resulting in destruction of β-cells, leading to absolute deficiency of
insulin. Indeed, poly I:C, a type of dsRNA commonly used to mimic viral infection, is
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able to effectively induce the onset of type I diabetes in C57BL/6 mice expressing
B7.1 on β-cells in the islets under a rat insulin promoter (RIP), which is IFN-α
dependent

[20]

. RNase L can be induced by both poly I:C and IFN-α in vitro and in

vivo, and medicates the functions of IFN-α. To determine the role of RNase L in the
onset of type I diabetes induced by poly I:C, RNase L deficient RIP-B7.1 mice were
created by cross-breeding an RNase L-/- mouse (C57BL/6) with a C57BL/6.RIP-B7.1
mouse (RIP-B7.1 mouse). The genotype of these mice was determined by PCR as
shown in Figure 2-3A. First, the onset of type I diabetes induced by using STZ, a
glucose analogue known to induce diabetes in experimental animals, in wild type and
RNase L deficient mice was investigated. Mice were interperitoneally (i.p.) injected
with 40 mg/kg STZ for five consecutive days, and the blood was collected from the
saphenous vein and the level of glucose was measured as described in the Methods.
As shown in Figure 2-3B, mice with RIP-B7.1 were more sensitive to STZ-induced
diabetic onset and RNase L deficiency markedly delayed the progress of this disease
in the RIP-B7.1 mice. To determine if RNase L mediates poly I:C induced onset of
type I diabetes, RNase L+/+ and

-/-

RIP-B7.1mice were be injected (i.p.) with 5 µg/g

body weight poly I:C daily for 7 days, and then immunized (i.p.) with insulin at 25
µg/mouse on day 14 after poly I:C treatment. Diabetic progress in these mice was
monitored every week and the mice were considered diabetic after two consecutive
blood glucose values ≥250 mg/dl. As shown in Figure 2-3C, the onset of diabetes was
significantly delayed in the RNase L deficient RIP-B7.1 mice.
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Figure 2-3. Effect of RNase L on STZ and poly I:C-induced diabetes
Genotyping of B7.1-RL-/- mice. B. Incidence of diabetes in RNase L (RL)+/+ and

A.
-/-

(n=10 for each group), B7.1-RL+/+ (n=8) and B7.1-RL-/- (n=9) mice after injection
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with 40mg/kg STZ for five consecutive days. C. Incidence of diabetes in B7.1-RL+/+
(n=9) and B7.1-RL-/- (n=8) mice after injected (i.p.) with 5 µg/g body weight poly I:C
daily for 7 days, and then immunized (i.p.) with 25 µg/mouse of insulin on day 14
after poly I:C treatment. The glucose levels in the blood samples were measured by
using a blood sugar test kit (Pointe Scientific). The mice were considered diabetic
after two consecutive blood glucose values ≥ 250 mg/dl.

2.3.4 RNase L facilitates infiltration of immune cells
RNase L is highly expressed in the thymus, spleen and all immune cells examined.
Since the infiltration of immune cells initiates the progress of this disease, we
attempted to investigate if the delay of type I diabetes onset is caused by slowdown of
immune responses in the pancreas of mice deficient RNase L. RNase L+/+ and

-/-

RIP-B7.1mice were treated with poly I:C for 40 days. The mice were sacrificed and
the pancreatic tissues were embedded and sectioned at 5 µm, subjected to
hematoxylin and eosin (H&E) staining. Interestingly, the population of infiltrated
immune cells was strikingly reduced in the islets of RNase L deficient mice,
suggesting the involvement of RNase L in poly I:C-induced diabetes onset may be
through regulating the infiltration of immune cells (Figure 2-4A). To determine the
identity of these infiltrated immune cells, immunohistostaining for macrophages, CD4
and CD8 T cells were performed. Apparently, the majority of the infiltrated immune
cells in the islets of the pancreas from RNase L
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+/+

mice was CD8 positive T cells

although some of CD4 positive T cells were found in the islets from both types of
mice (Figure 2-4B). However, macrophages were undetectable in the islets from both
types of mice by using either CD11b or F4/80 as a biomarker (data not shown).

The

finding indicates that CD8 positive T cells may be the effector cell in the destruction
of β-cells in the islets of the pancreas from RNase L+/+ RIP-B7.1 mice after poly I:C
treatment.

A.

RNase L +/+

Control)

Poly I:C
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RNase L -/-

B.
RNase L+/+

RNase L-/-

CD8+

CD4+

C.

Control

Poly	
  I:C

RNase L	
  -‐/-‐

RNase L	
  +/+

Figure 2-4. Infiltration of immune cells in the islets

A. Hematoxlin and eosin

stained pancreatic islets from B7.1-RL+/+ and B7.1-RL-/- mice after treatment with or
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without poly I:C. B. Immunohistological staining of CD4+ and CD8+ T cells in the
islets from both types of mice after poly I:C treatment. C. Immunohistological
staining of insulin in the islets from both types of mice before and after poly I:C
treatment. Magnification x 40.

2.3.5 The expression of proinflammatory cytokines in the pancreatic
tissues
In addition to IFN-α, several proinflammatory genes such as TNF-α, IL-1β and IFN-γ
are believed to contribute to the development of type I diabetes [11, 12]. To determine if
deficiency of RNase L results in any reduction of the expression of TNF-α, IL-1β,
IL-6 and IFN-γ, RNase L+/+ and

-/-

RIP-B7.1mice were treated with poly I:C at a

concentration of 5 µg/g body weight every other days for a week

and the level of

these gene products in the pancreatic extracts was determined by ELISA. As shown in
Figure 2-5, deficiency of RNase L reduced 37.5% and 48.5% of IFN-γ and TNF-α
production respectively induced in the pancreas by poly I:C although the expression
of IL-1β and IL-6 was found to be only slightly higher in the pancreas from RNase L
+/+

mice.
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Figure 2-5. RNase L regulates the expression of proinflammatory genes

RNase

L deficient and wild type RIP-B7.1 mice were treated with poly I:C at a concentration
of 5 µg/g body weight every other days for a week

and the level of these factors in

the pancreatic extracts was determined by ELISA using an ELISA kit for each of the
analyzers. Experiments were performed two times in triplicates. Data are presented as
mean ±SD.

2.4 Discussion and future studies
RNase L deficient mice RNase L null mice show enlarged thymus glands and
increased T cell numbers at their early age, which likely results from reduced cell
apoptosis, suggesting that RNase L may be involved in T cell development and
functions. Indeed, skin allograft rejection is suppressed in mice lacking RNase L,
implicating the involvement of RNase L in T cell immunity, particularly CD4+ T-cell
mediated immunity

[28]

. Alphavirus-based DNA vaccination against a non-mutated
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tumor-associate self-antigen (tyrosinase-related protein-1, TRP-1) is severely
impaired in RNase L null mice, indicating that RNase L plays an important role in
host immune system against cancer [29]. Our study revealed that lymphocytes isolated
from RNase L deficient mice displayed markedly attenuated cytotoxic activity (46%
lower) against retinal endothelial cells (data not shown). B7-1 and B7-2 are
homologous costimulatory ligands expressed on the surface of antigen presenting
cells (APCs). Binding of these molecules to the T cell costimulatory receptors, CD28
and CTLA-4, is essential for the activation and regulation of T cell immunity

[31]

.

Although expression of the B7.1 costimulator alone is not sufficient to induce
diabetes in mice, β-cells expressing the molecule are more vulnerable to
environmental harmful factors such as viral infection, resulting in destruction and
leading to disease

[32]

. As a mimic of viral infection, poly I:C treatment alone can

induce insulitis, but not diabetes in C57BL/6 mice. However, it can effectively
induce diabetes in C57BL/6 mice expressing B7.1 on β-cells in the islets under a rat
insulin promoter (RIP)

[20]

. In this study, we present evidence showing that RNase L

deficient RIP-B7.1 mice display a significant delay of type I diabetes onset induced
by poly I:C, suggesting that RNase L may be associated with the pathogenesis of this
disease.

RNase L mediating IFN functions against viral infection and cell proliferation has
been well established. A line of evidence has shown that IFN-α plays a vital role in
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initiating autoimmune responses although the molecular mechanism is continuing to
be a focus of investigation. Studies have revealed that type I diabetes onset in animal
models induced by STZ and poly I:C is IFN-α dependent [19, 20]. In human, incidences
in the development of type I diabetes have been widely documented during IFN-α
therapy for viral infection such as hepatitis B and C viral infection [33, 34]. How IFN-α
promoting the onset of type I diabetes remains to be further elucidated. RNase L is
one of the key enzymes in the 2-5A system of IFN-α function. 2-5A activation of
RNase L results in apoptosis in cells. It is believed that apoptosis is one of the key
factors in triggering autoimmune responses in islets

[35]

.

Thus, our results suggest

that poly I:C treatment may induce an increase of IFN-α production in islets and
subsequently activate the 2-5A system, leading to β-cell apoptosis, which further
promotes the autoimmune responses, resulting in destruction of all β-cells and
diabetes onset, and deficiency of RNase L in mice delays the onset of type I diabetes.
Actually, this hypothesis is supported by a previous study which poly I:C induces cell
apoptosis in pancreatic islets, resulting in release of islet autoantigens, triggering the
autoimmune responses. In contrast, none of the bacterial products such as LPS and
CpG are able to produce diabetes in these mice because they cannot induce islet cells
to undergo overt apoptosis [36].

RNase L may directly be involved in the function of immune cells to impact the
development of type I diabetes. Although T lymphocytes are primarily the effectors,
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studies have indicated that B cells may play a vital role in the pathogenesis of
autoimmune diseases. In NOD mice, the contribution of B cells was clearly
demonstrated by the remarkable reduction in insulitis and diabetes incidence after B
cell depletion using anti-IgM antibodies at birth or in NOD mice genetically deficient
in B cells

[37, 38]

. By using the same animal model, studies have shown that B cells

function as islet antigen–presenting cells for autoreactive T cells and produce
antibodies which are directly pathogenic. In clinical trials, patients with type I
diabetes treated with rituximab, a chimeric monoclonal antibody against the protein
CD20 that is primarily found on the surface of B cells, displayed partially preserved
β-cell function at one year post treatment as evidenced by decreasing C-peptide and
less insulin requirements, suggesting an essential role of B cells in the development of
this disease

[39]

.

Interestingly, the population of B220+/Ig D+ double labeled B cells

and CD4+/CD8+ double labeled T cells was 39% and 72% down after LPS treatment
(Figure 2-4A) or 46% and 45% down after poly I:C treatment (Figure 2-4B)

in the

spleen of RNase L deficient mice, implicating that delayed onset of type I diabetes
may be due to an attenuated immune responses as a result of that a harmful molecule
such as LPS or poly I:C decreases the population of certain immune cells. The effect
of RNase L on immunity is a focus of our investigation currently.

The production of proinflammatory genes in the islets plays a critical role in the
pathogenesis of type I diabetes. It has been demonstrated that disruption of IFN-γ
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function by using either IFN-γ specific Abs or soluble IFN-γ receptors (IFNγR)
significantly reduces the incidence of spontaneous diabetes in NOD mice, implicating
the importance of IFN-γ in the development of this disease [40, 41]. Complete protection
from diabetes was observed when TNFR1, but not TNFR2 was knocked out in NOD
mice although the direct effect of TNFR1 on β-cell death in vivo has not been defined
clearly [42]. It has been reported that RNase L mediates the expression of certain genes
through regulating RNA turnover

[43, 44]

. Our observation suggests that RNase L

specifically regulating the expression of proinflammatory genes in the pancreas may
contribute to type I diabetes onset induced by poly I:C. Thus, this study highlights the
potential benefits of targeting RNase L in type I diabetes treatment.
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CHAPTER III
QUANTITATIVE DETERMINATION OF HYM3
WITH LC-MS/MS
3.1 Introduction
Various steroidal derivatives have an anticancer effect. 6-Hydroximino-4-aza-Ahomo-cholest-3-one was found to be an effective drug candidate. In this study, an
analytical method has been developed to study the pharmacokinetics and
pharmacodynamic aspects of the drug candidate, and its metabolism characteristics in
mice. This project involved development and validation of a rapid and sensitive
LC-MS/MS method for determination of the compound in mouse plasma. Method
validation was fully performed according to the FDA guidelines.
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3.1.1 Method Summary
Sample preparation was realized by a protein precipitation procedure, and LC was
performed by using a Phenomenex-Kinetex-C8 column with a gradient mobile phase
of 0.2% formic acid in water and 0.2% formic acid in acetonitrile at a rate of 0.2
ml/min. For measurement, 10 µL of the supernatant was injected onto LC/MS system
consisting of a Shimadzu Prominence HPLC and an AB Sciex QTrap 5500 mass
spectrometer with positive electrospray ionization. A MRM mode was chosen for
sensitive and specific detection of the analyte and internal standard. The method
developed has been validated in mouse plasma according to the FDA guidance. The
quantitative assessment of Hym3 fills the gap of lacking analytical method for the
pharmacokinetic studies.

3.2 Material and methods
3.2.1 Chemicals and solutions
Hym3 and (3E)-hydroximinocholest-6-one, an internal standard (IS), were kindly
provided by the College of Chemistry and Life Science, Guangxi Teachers Education
University (Nanning, China).

Deionized water was collected from the Barnstead

NANOpure® water purification system (Thermo Scientific, Waltham, MA, USA).
Formic acid was purchased from Acros (Morris Plains, NJ, USA). Dimethylsulfoxide
(DMSO), HPLC-grade acetonitrile and ethyl acetate were obtained from Sigma–
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Aldrich (St. Louis, MO, USA). Pooled blank mouse plasma was from Equitech-Bio
(Kerrville, TX, USA).

Hym3 and IS stock solutions were prepared according to the following procedure:
first, the compounds were weighted out by an analytical balance and dissolved
separately into acetonitrile to a concentration of 1.00 mg/mL. For Hym3, the stock
solution was transferred into 1.5-mL microcentrifuge tubes as per aliquot of 100 µL.
For the IS, the stock solution was divided evenly into 25 µL per tube. Afterward, the
solution in the microcentrifuge tubes was dried in a DNA120 SpeedVac®
(ThermoSavant, Hollbrook, NY, USA) vacuum evaporator at 25℃ and the dried
stocks were kept at −20℃ until use. Before use, 1.00 mL of deionized water was
added into the microcentrifuge tube to make the working solution of Hym3 and IS at
100 and 25.0 µg/mL, respectively. The Hym3 and the IS working solutions were
freshly prepared before analysis. The mobile phase of LC was prepared by a gradient
mobile phase of 0.2% formic acid in water and 0.2% formic acid in acetonitrile at a
rate of 0.2 ml/min.

3.2.2 LC-MS/MS instrumentation
The LC–MS/MS system was composed by a Shimadzu Prominence HPLC and an AB
Sciex QTrap 5500 mass spectrometer (AB Sciex, Toronto, Canada) with positive
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electrospray ionization. The HPLC unit included two binary pumps, a degasser, an
autosampler, an inline Phenomenex filter (0.5 µm pore) a Phenomenex Kinetex C8
column (50x2.1 mm, 2.6µ) (Torrance, CA, USA) and Analyst software version 1.4.2
was utilized for the LC–MS/MS system operation, data acquisition and processing.
For each LC-MS/MS analysis, the injection volume of the sample onto the column
was 10 µL. Isocratic elution was utilized in the chromatographic separation. The flow
rate was set as 200 µL/min. The post-column switching valve was programmed so
that only the column eluate after 5.0 min was diverted to the mass spectrometer for
analysis. The positive electrospray- ionization (ESI+) mode was adopted when
operating the mass spectrometer. The mass spectrometer was tuned by direct infusion
of a solution containing 10.0 µg/mL of Hym3 and 10.0 µg/mL of IS dissolved in the
mobile phase. The flow rate of infusion was set as 3 µL/min with a syringe pump
(Harvard Apparatus, South Natick, MA, USA). Full mass spectrometric scans of
HyM3 and IS showed protonated molecular ions of 431 and 416 m/z, and
fragmentation of these two precursor ions revealed predominant product ions of 370
and 344 m/z respectively. MRM channels were set at m/z 431→370 for HyM3 and
416→344 for IS.

The optimized parameters for detecting Hym3 and IS were set as

following: the ion spay voltage (IS) was 5500 eV; the temperature was at 300℃; the
heating gas (GS1), nebulization gas (GS2), and Curtain gas (CUR) were 45, 45, and
20 psi, respectively. Compound parameters, including declustering potentials (DP),
entrance potential (EP), collision energy (CE), and collision exit potential (CXP) for
both Hym3 and IS were set at 90, 7.0, 15.0, and 20V, respectively.
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3.2.3 Preparation of standard solutions and plasma controls
Hym3 standard solutions at the concentration of 10.0, 20.0, 40.0, 100.00, 200.0, 400.0,
1000.0, 2000, and 4000 ng/mL were prepared by a serial dilution of 100 µg/mL Hym3
working solution. The IS was diluted from the 100 µg/mL working solution to 400.0
ng/mL.

The calibrators (0.500, 1.00, 2.00, 5.00, 10.0, 20.0, 50.0, 100, and 200 ng/mL) of
Hym3 in mouse plasma were obtained individually by mixing 200 µL of pooled blank
plasma, together with 5.0 µL of Hym3 standard solution (at twenty times of the
concentration of the related calibrator) and 10.0 µL of IS standard solution at 400
ng/mL.

3.2.4 Protein precipitation of Hym3
Plasma calibrators, controls and animal samples were extracted by using a protein
precipitation protocol: 800 of ACN were mixed with the plasma sample in a 1.5mL
microcentrifuge tube. Then, the sample was subjected to a short vortex for 1 min,
followed by a centrifugation at 13000×g for 10 min. Next, 85% of the organic (upper)
layer (ca. 850 µL) was transferred into a clean 1.5-mL microcentrifuge tube and dried
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by vacuum evaporation on the DNA 120 SpeedVac® at 25 ℃. The sample residue
was finally reconstituted with 850 µL of deionized water.

3.2.5 Matrix effect and recovery studies
To study the matrix effect, 200 µL pooled blank plasma mixed with 10 µL of water
was extracted with the protocol described in Section 3.2.4. Afterward, a mixture of
Hym3 and the IS standard solutions were spiked into the post-extract matrix. The
prepared samples possessed Hym3 of 1.25, 15.0 and 180 ng/mL, and the IS of 20.0
ng/mL. The peak area ratios of Hym3 to IS in the spike-after-extraction (SAE)
standards were compared with those of the corresponding authentic pure standards.

To obtain the recovery data, Hym3 plasma calibrators (1.25, 15.0 and 180 ng/mL,
with the IS at 20.0 ng/mL) were analyzed. IS normalized recovery of Hym3 was
calculated by comparing the peak area ratios of Hym3 to IS in the plasma calibrators
with those of the corresponding SAE standards. The absolute recovery of the IS was
obtained by comparing the peak areas of the IS in the plasma calibrators with those of
the corresponding SAE standards.
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3.2.6 Stability studies
Mouse plasma test controls (1.25 and 180 ng/mL) were prepared as described in
Section 3.2.3 except the IS standard was added prior to the LLE. All experiments
were run in triplicate and the results were compared with freshly prepared plasma
controls. For the freeze and thaw stability study, the test controls were undergone
three freeze and thaw cycles. In each cycle, the test controls were frozen at −20℃for
at least 24 h and thawed at room temperature without help. The short-term
temperature stability study was carried out by leaving the test controls at the room
temperature (25℃) for 4–24 h. For the long-term stability, the test controls were
stored at −20℃ for 90 days prior to analysis.

3.3 Results and discussions
3.3.1 Method development

Mass spectrometric detection of Hym3 and the IS
In this study, “auto-tune” function of the analyst software was utilized for the
instrument response optimization. Due to their chemical properties, Hym3 and the IS
can form protonated species more easily than the deprotonated species through
electrospray ionization. Thus, the positive electrospray ionization mode was utilized
for the identification and quantification of Hym3 and the IS. Figure 3.1 A and B
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demonstrates the predominant molecular ions of Hym3 and the IS at m/z 431 for
[Hym3+H]+ and m/z 416 [IS+H]+, respectively. With collision-induced-dissociation
(CID) introduced by argon gas in the second quadrupole, these two molecular ions
were further dissociated into product ions illustrated in Figure 3.1 C and D,
respectively. The major product ion of the protonated Hym3 and the IS were shown at
m/z 370 and m/z 344, respectively. As a result, MRM channels were set at m/z 431→
370m/z for HyM3 and 416→344 m/z for the internal standard. To understand the
fragmentation mechanisms in CID, the m/z difference of the compound before and
after CID were compared. Summarized with the structural information of the
compounds, the proposed fragmentation mechanism is shown in Figure 3-2.

Figure 3-1. The mass spectra of Hym3 and the internal standard

100

Figure 3-2. The proposed fragmentation bonds of Hym3 and the IS.

LC separation of Hym3
Both compounds can be considered as more hydrophobic than hydrophilic. Based on
this information, three C-18 reverse phase columns, a Phenomenex Gemini® columns
(2.0mm×50mm, 5 µm particle size with 110Å pore size) and a YMC ODS-AQ®
column (2.0mm×50mm, 5 µm particle size with 120Å pore size) and a C8 a
Phenomenex Kinetex C8 column (50x2.1 mm, 2.6µ) have been tried for optimized LC
separation. Both columns successfully retained Hym3 and the IS on the column for
over 3 column volumes and were able to provide base line separation between Hym3
and the IS. However, the Phenomenex Kinetex C8 column was able to provide better
peak shape compared to the other columns. Meanwhile, since Hym3 and the IS are
basic compounds, 0.2% of formic acid was added into the mobile phase in order to
facilitate the protonation of the analytes, which enhanced the sensitivity of MS
detection.
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The increased hydrophilicity of the analyte after the addition of the formic acid also
reduced the retention times of the analyte and the IS, leading to shorter retention time
and faster LC analysis.

To optimize the separation efficiency, the percentage of acetonitrile in the mobile
phase was adjusted. Although a complete baseline resolution between Hym3 and the
IS could be achieved with a mobile phase consisted of 35.0% acetonitrile, 0.2%
formic acid and 65% deionized water (v/v/v), the total LC time was as long as 5 min,
but the Matrix effect was too big to use the isocratic elution. To eliminate the
interferences between the two compounds, a gradient mobile phase of 0.2% formic
acid in water and 0.2% formic acid in acetonitrile at a rate of 0.2 ml/min was applied
(Figure 3-3).
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Figure 3-3. Representative MRM chromatograms of analytes in mouse plasma.

Fig.3-3 Representative MRM chromatograms of analytes in mouse plasma

(A)

double-blank plasma (no Hym3 detected); (B) 0.50 ng/mL Hym3 in plasma (at LLOQ
with a S/N of 17.2); (C) 18.0 ng/mL Hym3 in plasma; (D) double-blank plasma (no IS
detected); and (E) 20 ng/mL IS in plasma.

3.3.2 Method validation
The performance of the method developed was validated according to the FDA
guidance for industry bioanalytical method validation [1].
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Matrix effect and recovery studies

In the studies of matrix effect and recovery, triplicate measurements were performed
for each of three different concentration levels (i.e., low, medium, and high). The
matrix effect was normalized by the signal of the Matrix Factor of IS (MFIS), and thus
was calculated with the equation as following:

A represents the peak area of the analyte; while A’ indicates the peak area of the IS.
(A/A’) indicates the peak area ratio of the analyte to the IS. Thus, (A/A’)

matrix

indicates the peak area ration in the post-extraction matrix and (A/A’) solvent indicates
that in pure solvent.

As Table 3-1 illustrated, the MFIS in mouse plasma matrices varied between 1.03-1.10.
Meanwhile, the values of MFIS were quite consistent over the concentration range
reproducible with standard deviation (SD) ≤0.02.
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To reduce the variation caused by instrument, the recovery was also studies as the IS
normalized form (RIS). It was calculated with the equation below:

(A/A’) extraction represents the peak area ratio in extracted plasma samples.

The summarized recovery data can be viewed in Table 3-1. The values ranged from
97 to 98%. The absolute recoveries (RC’) of the IS from both plasma samples were
also calculated by using the equation below:

Here A’extraction stands for the peak area of the IS in the extracted plasma sample;
while A’matrix represents the peak area of the IS in the post-extraction matrix. The
values of RC’ ranged from 96 to 99% in mouse plasma and the results were
reproducible and consistent within the calibration range.

Table 3-1. Matrix effect and recovery
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Calibration of curve, accuracy, and precision
The calibration curve of Hym3 in mouse plasma was established with nine non-zero
plasma calibrators. For each set of calibrator, one double-blank (with neither Hym3
nor IS) plasma sample and one zero (with IS only) plasma sample were also included.
The concentrations of Hym3 for the non-zero calibrators were 0.50, 1.00, 2.00, 5.00,
10.0, 20.0, 50.0, 100 and 200 ng/mL. The linear calibration curves ranged from 0.50
to 200 ng/mL were established by plotting A/A’ in mouse plasma versus the
concentrations of Hym3. The weighting factor for both calibration curves were
utilized as 1/x (the reciprocal of Hym3 concentration). Both calibration data were
given in Table 3-2. In the determination of the lower limits of quantification (LLOQ),
the plasma calibrator with the lowest concentration, yet still fit in the calibration curve
with acceptable accuracy and precision. The concentrations of the calibrators were
back-calculated according to the calibration equation with the information of the A/A’.
The accuracy and precision were calculated as they have been described in the
previous chapter. The accuracy and precision for the mouse plasma ranged from 1 to
3% and from 3 to 5%, respectively. All values fell within the acceptable criteria (i.e.,
≤±15% at all concentrations except at LLOQ where ≤±20%) suggested by the
FDA guidance.

The precision of the method was evaluated in two aspects: the intra-and inter assay
precisions. To determine the precisions, five replicates of plasma control samples at
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low-, mid- and high-concentration levels (LQC, MQC and HQC) were prepared and
analyzed. The accuracies of the above studies were between 1 to 4% (Table 3-3). As
expected, they fell well within the acceptable criteria suggested by the FDA guidance.

Table 3-2. Data for calibration equations of Hym3 in mouse plasma

Calibration Equations: Mouse plasma: Y = 0.0385 (± 0.012) x - 0.00107 (± 0.00304)
(r2= 0.999 ± 0.000)

Each measured concentration was based on three measurements carried out on three
different days and the S.D. values showed in the table indicated the standard deviation
of each triplicate measurement. The calibration equations were based on three
separate measurements carried out on three different days.
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Table 3-3. Accuracy, intra- and inter-assay precisions of Hym3 in mouse plasma.

The concentration of LQC, MQC and HQC of Hym3 were 1.25, 15 and 180 ng/mL,
respectively. The concentration of IS was 20.0ng/mL.

Stability studies
Two concentration levels, 1.25 and 180 ng/mL, were utilized in the stability test.
Triplicate measurements were performed at each concentration level. The stability
results were summarized in Table 3-4. As shown in the table, no significant loss of
Hym3 was observed in mouse plasma under the storage conditions and its recovery
ranged between 96 and 98% after stored at room temperature for 24 h and three
freeze-and-thaw cycles. In addition, a long-term storage of HYM3 in mouse plasma at
-20 ℃ also showed adequate recoveries. Based on these experimental facts, we
conclude that Hym3 is pretty stable in either its stock solution or the spiked mouse
plasma, which is important for deciding the operative time in pharmacokinetic study
of the drug candidate in the future.
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Table 3-4. Stability data of Hym3 under different test conditions

3.3 Conclusions and future studies
Based on all the experimental data as described above, a quantitative LC–MS/MS
method for the assessment of Hym3 in mouse plasma has been developed. In brief,
the analytes in mouse plasma were extracted by ethyl acetate, separated by
Phenomenex Kinetex C8 column (50x2.1 mm, 2.6µ), and then analyzed through the
tandem mass spectrometry. Method validation has been performed in mouse plasma
according to the FDA guidance. The linear range of the method was from 0.50 to
200ng/mL in mouse plasma. Due to its high accuracy, precision, and sensitivity, the
method will be useful for studying pharmacokinetics and pharmacodynamics of
Hym3 in its preclinical and clinical trials as a potent drug candidate for cancer
treatment in the future.
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